Bongiovanni, A.; Nicolini, S.; Ibrahim, T.; Foca, F.; Sansovini, M.; Di Paolo, A.; Grassi, I.; Liverani, C.; Calabrese, C.; Ranallo, N.;
et al. 177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials. Cancers 2022, 14, 6022.
https://doi.org/10.3390/cancers14246022
AMA Style
Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M, Di Paolo A, Grassi I, Liverani C, Calabrese C, Ranallo N,
et al. 177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials. Cancers. 2022; 14(24):6022.
https://doi.org/10.3390/cancers14246022
Chicago/Turabian Style
Bongiovanni, Alberto, Silvia Nicolini, Toni Ibrahim, Flavia Foca, Maddalena Sansovini, Arianna Di Paolo, Ilaria Grassi, Chiara Liverani, Chiara Calabrese, Nicoletta Ranallo,
and et al. 2022. "177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials" Cancers 14, no. 24: 6022.
https://doi.org/10.3390/cancers14246022
APA Style
Bongiovanni, A., Nicolini, S., Ibrahim, T., Foca, F., Sansovini, M., Di Paolo, A., Grassi, I., Liverani, C., Calabrese, C., Ranallo, N., Matteucci, F., Paganelli, G., & Severi, S.
(2022). 177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials. Cancers, 14(24), 6022.
https://doi.org/10.3390/cancers14246022
